drugset
Drugs / Meglumine Sodium Succinate
last change May 2025 re-read 3 minutes ago

Meglumine Sodium Succinate

also known as meglumin sodium succinate · REAMBERIN
Developed for
diabetic ketoacidosis · metabolic acidosis
Investigated by
POLYSAN Scientific & Technological Pharmaceutical Company · Atlant Clinical Ltd.

Trials 2

today NCT06955416 · Ph 2/3 NCT05147051 · Ph 2
2022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT05147051 Jun 2021 → May 2022 metabolic acidosis POLYSAN Scientific & Technological Pharmaceutical Company Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT06955416 May 2025 → Dec 2027 expected diabetic ketoacidosis POLYSAN Scientific & Technological Pharmaceutical Company Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Meglumine Sodium Succinate ClinicalTrials.gov intervention name — accepted as the source's own label NCT05147051 ↗
Known as meglumin sodium succinate “REAMBERIN® (meglumin sodium succinate), a 1.5% infusion solution” NCT06955416 ↗
Known as REAMBERIN “REAMBERIN® (meglumin sodium succinate), a 1.5% infusion solution” NCT06955416 ↗
Route Intravenous “500 ml intravenously every 8 hours” NCT05147051 ↗